Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Cuts Q4 Revenue Projection for Second Time

NEW YORK, Jan. 6 (GenomeWeb News) - Affymetrix announced yesterday cut its fourth-quarter revenue projections by roughly $15 million, or 12.5 percent, below previous guidance.


The company blamed the cut, which is the second one in three months, on low fourth-quarter instrument sales and delays in completing genotyping processing under a services contract.


Affymetrix had originally projected its Q4 revenues to be $130 million. In the fall of 2005, the company cut this projection to $120 million.


Affy also cut its full-year 2005 product-related revenue projection, also for a second time. The company originally projected to generate $390 million in product-releated receipts in 2005, but in the fall of 2005, the firm cut that figure 6 percent to $365 million. Yesterday, Affy further cut that projection, this time to $350 million, or an additional 4.3 percent.


Also yesterday, Affy cut its total 2005 revenue projection by $40 million, or 9.9 percent, to $365 million.


"Affymetrix is experiencing growing pains as it both innovates and commercializes new products in high potential markets," said CEO Stephen Fodor. "We are carrying record orders into 2006 and expect to achieve around 15 percent top-line growth for the full year."

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.